← Back to Home

New Cancer Therapies Approach a Validation Milestone: What Signals Are Emerging from Brain, Breast and Colorectal Cancer Research?

Intranasal delivery, immunotherapy combinations and viral therapy have each yielded early data or regulatory progress. But assessment criteria, trial controls and approval pathways that remain unsettled determine how far these developments are from treatment breakthroughs.

By SURL BioNews

For patients whose cancer has recurred or who have undergone multiple rounds of treatment, the most important promise of new therapies is more time with their disease under control. Research and regulatory announcements from NeOnc, BriaCell and Oncolytics between June and August 2026 each represent progress toward that goal. However, the evidence for the three programs is at different stages of maturity: preliminary survival data, blinded analyses and regulatory feedback cannot be treated as equivalent confirmation of efficacy.

On August 12, NeOnc announced preliminary Phase 2 results for its intranasal drug candidate NEO100. The single-arm, open-label trial enrolled 24 patients with recurrent or progressive grade 3 or 4 gliomas harboring an IDH1 mutation. An analysis using the RANO 2.0 brain tumor response assessment criteria estimated the six-month progression-free survival rate at 48.9%, above the prespecified historical benchmark of 20%. The company also reported median overall survival of 26.09 months.

But the same data also revealed a key difference: a presentation NeOnc submitted to the U.S. Securities and Exchange Commission stated that, under the RANO criteria originally specified in the trial protocol, the six-month progression-free survival rate was 25.8%, and the difference from the historical benchmark was not statistically significant. The claim that the primary endpoint was met must therefore be understood in conjunction with the analytical method used. With no concurrent control group in the trial, the survival figures also cannot yet establish that the drug is superior to existing treatments.

The breast cancer research shifts the focus to treatment combinations and sequencing. BriaCell's Phase 2 analysis, presented at the American Society of Clinical Oncology annual meeting in June, covered 32 patients with metastatic breast cancer who had received a median of six prior treatments. Among them, patients receiving the Bria-IMT plus immune checkpoint inhibitor regimen selected for the subsequent Phase 3 trial had median overall survival of 16.6 months. This result applies to patients receiving that specific regimen, rather than all 32 patients, and cannot be directly translated into a survival gain over standard treatment.

BriaCell said there were no treatment-related discontinuations or unexpected safety signals in the study; the small sample remains insufficient to rule out less common risks. Data from the Phase 3 Bria-ABC trial presented at the same meeting concerned quality of life and blood biomarkers, and the analysis remained blinded at the time. These data may help clarify patients' condition and which indicators are associated with the course of disease, but they cannot yet establish that the Bria-IMT group performed better than the control group.

The progress Oncolytics announced on August 18 centered on the design of subsequent trials. The company said it had received written feedback from the U.S. Food and Drug Administration on potentially expanding the REO 033 study into a pivotal trial. The study involves second-line treatment for RAS-mutated, microsatellite-stable metastatic colorectal cancer. Part A plans to enroll 60 patients, randomly comparing pelareorep added to FOLFIRI chemotherapy and bevacizumab with the same chemotherapy and bevacizumab alone.

The company is seeking to use objective tumor response rate and duration of response to support potential accelerated approval, followed by progression-free survival to support full approval. However, the FDA recommended a separate end-of-phase meeting to finalize key details of the registration program, prompting the company to cancel the previously scheduled Type D meeting. Whether the pivotal Part B expansion can begin still depends on supportive clinical results from Part A; this feedback does not constitute marketing approval.

Together, the three programs illustrate the reality of cancer drug development: after a signal emerges, it must still withstand scrutiny under different assessment methods, controlled trials and longer follow-up. The brain tumor study needs to clarify the differences arising from its assessment criteria, the breast cancer regimen awaits comparative results, and the colorectal cancer program must first generate sufficient data to advance to the next stage before development hopes can gradually become credible evidence for treatment.

References

  1. marketscreener.com
  2. BriaCell Therapeutics Corp.
  3. Oncolytics Biotech Inc. — SEC-hosted press release